Compare VECO & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VECO | DFTX |
|---|---|---|
| Founded | 1945 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1996 | N/A |
| Metric | VECO | DFTX |
|---|---|---|
| Price | $34.25 | $20.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $27.25 | ★ $40.25 |
| AVG Volume (30 Days) | 976.1K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $664,294,000.00 | N/A |
| Revenue This Year | $16.39 | N/A |
| Revenue Next Year | $12.40 | N/A |
| P/E Ratio | $58.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.92 | $14.62 |
| 52 Week High | $37.23 | $21.10 |
| Indicator | VECO | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 65.59 |
| Support Level | $27.99 | $16.41 |
| Resistance Level | $36.50 | N/A |
| Average True Range (ATR) | 1.87 | 1.08 |
| MACD | 0.19 | 0.21 |
| Stochastic Oscillator | 59.86 | 89.53 |
Veeco Instruments Inc is a United States-based company engaged in designing, developing, and manufacturing thin-film process equipment, mainly used for producing electronic devices. The company focuses on semiconductor process equipment that addresses a range of challenging materials engineering problems for its customers. Its products include Laser Processing Systems, Lithography Systems, Ion Beam Systems, SiC CVD Systems, MOCVD Systems, Wet Processing Systems, MBE Technologies, Atomic Layer Deposition Systems, Physical Vapor Deposition Systems, Dicing and Lapping Systems, as well as Gas & Vapor Delivery Systems. The maximum of the company's revenue is generated from sales to the Semiconductor Industry and within China.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).